重组人血小板生成素治疗化疗后血小板减少的临床观察

目的评价重组人血小板生成素（rhTPO）治疗化疗后血小板减少的疗效和安全性。方法 45例恶性肿瘤患者在化疗后出现血小板减少,随机分为A组和B组,A组皮下注射rhTPO（15 000U/d）,B组皮下注射白细胞素-Ⅱ（1.5mg/d）,动态监测注射后血小板生长情况。结果 A组血小板计数的最低值明显高于B组（P〈0.01）;A组血小板开始恢复时间为较B组明显缩短（P〈0.01）;血小板恢复至100×109/L以上所需时间A组也较B组明显缩短,分别为：（6.18±4.20）d和（10.46±4.54）d（P〈0.05）;血小板恢复的最高值两组差异无统计学意义（P〈0.05）;B组有2例患者化疗后需要输注外源性血小板,而A组无1例患者需要输注血小板;与B组比较,A组较少发生不良反应,患者可以耐受。结论重组人血小板生成素治疗后出现的血小板减少安全有效。

Clinical observation on recombinant human thrombopoietin for treatment of chemotherapy-induced thrombocytopenia

Objective To evaluate the effect and safety of recombinant human thrombopoietin（rhTPO） to the thrombocytopenia patients.Methods Forty-five tumor patients with platelet count75×109/L after chemotherapy were enrolled into this stuty.They were divided into group A and group B.Patients in group A were given rhTPO 15 000U/d hypodermic injection and patients in group Bwere given recombinant human interleukin-11 1.5mg/d,platelet count was checked consecutively.Results In group A,the minimal platelet count was significantly higher than that of group B（P0.01）.The time of declined platelet count beginning to recover was significantly shorter in group A than that in group B.The time of platelet count increasing to 100×109/L was within（6.18±4.20） days,significantly shorten compared with group B（10.46±4.54） days.However,no significant was found among the two groups in the maximal platelet count（P0.05）.Two patients were needed platelet transfusion in group B and patients in group A weren′t needed.Conclusion Recmbinant human thrombopoietin can promote recovery of platelet of tumor patients after chemotherapy and no significant adverse effect.